In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates

被引:143
作者
Owen, Roxanne J. [1 ]
Li, Jian [1 ]
Nation, Roger L. [1 ]
Spelman, Denis [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Facil Antiinfect Drug Dev & Innovat, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
killing kinetics; heteroresistance; post-antibiotic effect;
D O I
10.1093/jac/dkl512
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background. Colistin is being increasingly used for treatment of infections caused by multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. Methods: The in vitro pharmacodynamic properties of colistin (sulphate) were investigated by studying the time-kill kinetics and the post-antibiotic effect (PAE) against multidrug-resistant, including colistin heteroresistant, A. baumannii. Time-kill was studied with four multidrug-resistant clinical isolates at concentrations ranging from 0.5 to 64x MIC. The PAE was examined after 20 min exposure with five clinical isolates, including the four in the time-kill study, plus ATCC 19606. Results: Colistin showed extremely rapid killing in a concentration-dependent manner; but re-growth was observed as early as 3 h and substantial re-growth at 24 h even at concentrations up to 32x MIC or 64x MIC for some isolates. Colistin exhibited modest PAE of 1.0, 2.3 and 3.5 h at 16, 32 and 64x MIC, respectively, against ATCC 19606. Surprisingly, negative PAE (range: -0.8 to -8.15 h) was observed for all of the five clinical isolates. Conclusions: These findings suggest that monotherapy with colistin methanesulphonate, the parenteral form of colistin, and long dosage intervals (e.g. 24 h) may be problematic for treatment of infections caused by colistin heteroresistant A. baumannii.
引用
收藏
页码:473 / 477
页数:5
相关论文
共 23 条
  • [1] Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
    Al-Aloul, M
    Miller, H
    Alapati, S
    Stockton, PA
    Ledson, MJ
    Walshaw, MJ
    [J]. PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 15 - 20
  • [2] ANTONIADOU A, 2005, 45 ANN INT C ANT AG, P342
  • [3] Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa
    Bergen, Phillip J.
    Li, Jian
    Rayner, Craig R.
    Nation, Roger L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 1953 - 1958
  • [4] Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features
    BergogneBerezin, E
    Towner, KJ
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) : 148 - +
  • [5] Multidrug-resistant Acinetobacter extremity infections in soldiers
    Davis, KA
    Moran, KA
    McAllister, CK
    Gray, PJ
    [J]. EMERGING INFECTIOUS DISEASES, 2005, 11 (08) : 1218 - 1224
  • [6] GILAD J, 2005, 45 ANN INT C ANT AG, P333
  • [7] PHARMACODYNAMIC EFFECTS OF MEROPENEM ON GRAM-NEGATIVE BACTERIA
    HANBERGER, H
    SVENSSON, E
    NILSSON, LE
    NILSSON, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (05) : 383 - 390
  • [8] EFFECTS OF IMIPENEM ON ESCHERICHIA-COLI STUDIED USING BIOLUMINESCENCE, VIABLE COUNTING AND MICROSCOPY
    HANBERGER, H
    SVENSSON, E
    NILSSON, M
    NILSSON, LE
    HORNSTEN, EG
    MALLER, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (02) : 245 - 260
  • [9] Post-antibiotic effect of the antimicrobial peptide lactoferricin on Escherichia coli and Staphylococcus aureus
    Haukland, HH
    Vorland, LH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) : 569 - 571
  • [10] *INF DIS SOC AM, 2004, BAD BUGS NO DRUGS